CMAB Biopharma provides bespoke development and manufacturing services for antibodies and biologics, offering process development, analytical methods, formulation, and manufacture of biologic drug substances and products. Led by President Qibin Liang, the company serves clients in China and globally from a facility in Suzhou’s BioBAY Park. The company’s new manufacturing facility will produce pre-clinical and early-stage clinical (Phase I/II) products following global GMP standards. CMAB plans to upgrade its 2,000L GMP facilities and expand capacity to offer 50L/200L/500L/1,000L/2,000L bioreactor scale GMP manufacturing services. The facility and operations are stated to follow standards of the China Food & Drug Administration, US FDA (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH guidelines. The article reports a recent financing to support these expansion and upgrade plans. CMAB Biopharma is a full-service contract development and manufacturing organization (CDMO) based in BioBAY Park, Suzhou, China, offering process development and manufacturing for biologic products. The company provides development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products. Initial services target generation of pre-clinical and early-stage clinical (Phase I/II) products for Chinese and global clients. CMAB follows global GMP standards, including CFDA, US FDA (21 CFR), EMA (Eudralex), WHO, and harmonized PIC/S and ICH guidelines. Led by President Liang Qibin, the company currently has 65 employees and plans to expand to 180 staff within one year. The business offers bespoke antibody and biologics development and manufacturing services for clients in China and across the globe.

Total raised

$72M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2018